FDA Breakthrough Device Designation
← All team
Frank Cheng
Team

Frank Cheng

CEO and Board Member

Frank spent the last 30 years in chief executive and top commercial roles with both established and emerging medical technology companies.

Frank started his career with GE Healthcare in diagnostic imaging and patient monitoring, where he led company-wide marketing and strategic planning projects and supported a major M&A transaction. He then served as Vice President at Roche Diagnostics, leading global business development initiatives.

For over seven years Frank was Senior Vice President and the top commercial and operations leader at Stereotaxis, Inc., a publicly traded company focused on robotic surgery for cardiac and vascular procedures, with a portfolio that included a million-dollar robotic system and multiple FDA-approved surgical disposables. The company achieved hundreds of millions of dollars in revenue during this period.

From 2019 to 2023 Frank was President and Chief Commercial Officer at Eyenuk, Inc., a diagnostics company whose autonomous AI technology was FDA-cleared, Medicare-reimbursed, supported by a new Category I CPT code, and adopted around the world.

Before joining BlackLight Surgical, Frank led Caristo Diagnostics as CEO for about four years. Caristo developed imaging-based, AI-assisted platforms for diagnosing heart and vascular disease, was named by Newsweek one of the world's Best Digital Health Companies, and was selected by the World Economic Forum as a Technology Pioneer. Under Frank's leadership Caristo received FDA de novo authorization for its coronary inflammation detection technology and FDA 510(k) clearance for its coronary plaque quantification technology, and grew rapidly after the American Medical Association approved new CPT codes for its technologies.